Inventiva (NASDAQ:IVA - Free Report) had its price target increased by Canaccord Genuity Group from $12.00 to $20.00 in a research report sent to investors on Monday, Benzinga reports. Canaccord Genuity Group currently has a buy rating on the stock.
A number of other brokerages have also commented on IVA. Lifesci Capital reiterated an outperform rating on shares of Inventiva in a research report on Friday, January 5th. HC Wainwright reiterated a buy rating and issued a $22.00 price objective on shares of Inventiva in a research report on Monday, April 1st. Finally, Stifel Nicolaus lowered their price objective on Inventiva from $27.00 to $25.00 and set a buy rating for the company in a research report on Friday, February 16th. Eight equities research analysts have rated the stock with a buy rating, According to MarketBeat, the stock has a consensus rating of Buy and an average target price of $17.00.
Check Out Our Latest Research Report on Inventiva
Inventiva Stock Performance
Shares of NASDAQ:IVA traded up $0.08 during midday trading on Monday, reaching $3.86. The company's stock had a trading volume of 115,220 shares, compared to its average volume of 38,182. Inventiva has a fifty-two week low of $2.22 and a fifty-two week high of $5.05. The business's fifty day simple moving average is $3.71 and its 200-day simple moving average is $3.97.
Hedge Funds Weigh In On Inventiva
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in IVA. Morgan Stanley lifted its holdings in shares of Inventiva by 300.0% during the 4th quarter. Morgan Stanley now owns 6,000 shares of the company's stock valued at $27,000 after purchasing an additional 4,500 shares in the last quarter. Citigroup Inc. lifted its holdings in shares of Inventiva by 91.7% during the 1st quarter. Citigroup Inc. now owns 23,000 shares of the company's stock valued at $84,000 after purchasing an additional 11,000 shares in the last quarter. Finally, Commonwealth Equity Services LLC bought a new position in shares of Inventiva during the 1st quarter valued at about $51,000. Institutional investors own 19.06% of the company's stock.
Inventiva Company Profile
(
Get Free Report)
Inventiva SA, a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH) and other diseases. Its lead product candidate is Lanifibranor, which is in Phase III clinical trial to treat NASH. The company also develops Odiparcil, which has completed Phase IIa clinical trial for the treatment of mucopolysaccharidoses type VI disease.
Featured Stories
Before you consider Inventiva, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Inventiva wasn't on the list.
While Inventiva currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Growth stocks offer a lot of bang for your buck, and we've got the next upcoming superstars to strongly consider for your portfolio.
Get This Free Report
